Kwality Pharma Share Price: 52-Week High ka record toda! Record Revenue aur Dividend ka Dhamaka!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Kwality Pharma Share Price: 52-Week High ka record toda! Record Revenue aur Dividend ka Dhamaka!
Overview

Arre bhaiyo, Kwality Pharma ke share price ne aaj kamaal kar diya! Stock **10%** se zyada bhaga aur naya **52-week high** bana dala. Company ne zabardast quarterly results report kiye hain, revenue ne record toda hai aur profit bhi bada hai. Saath mein **dividend** ka bhi announcement hua hai, jisse investors ka confidence aur badh gaya.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Bade stock market mein aaj Kwality Pharmaceuticals ke liye ekdum positive din raha. Share ka price seedha ₹2,206.55 tak pahunch gaya, jo ki 10% se bhi zyada ki tezi thi aur iska 52-week high hai.

Is sab ka reason company ka Q4FY26 ka performance hai. Unhone apna ab tak ka sabse zyada quarterly revenue report kiya hai, jo ki ₹157.11 crore hai. Pichhle saal isi quarter mein yeh ₹115.67 crore tha, matlab 35.8% ka growth! Aur toh aur, company ne FY26 ke liye ₹2 per equity share ka dividend bhi announce kiya hai.

Poore Saal Ka Performance Bhi Solid!

Full FY26 ki baat karein toh, Kwality Pharma ka consolidated revenue ₹503 crore raha, jo FY25 ke ₹370 crore se 36% zyada hai. Unka EBITDA margin bhi 24% ho gaya hai, jo pehle 22% tha. Yeh sab improve hua hai kyunki unka product mix acha ho gaya hai, regulated markets se contribution badha hai, aur Mexico aur Colombia jaise regions mein business grow kar raha hai.

Profitability Mein Bada Jump!

Revenue se bhi zyada profit bada hai. FY26 mein Profit After Tax (PAT) ₹67.34 crore raha, jo FY25 ke ₹39.80 crore se lagbhag 69% zyada hai. PAT margin bhi 10.8% se badhkar 13.4% ho gaya hai. Company keh rahi hai ki yeh sab operational efficiency, achhe realisation, aur strict cost control ki wajah se hua hai.

Future Ka Outlook Kya Hai?

Company ne FY27 ke liye apna guidance reaffirm kiya hai. Unko ₹650 crore ka revenue aur ₹100 crore ka PAT expect hai. Management ko lagta hai ki agar international markets mein approvals aur registrations jaldi hue toh yeh targets aur bhi badh sakte hain. Goal toh yeh hai ki agle teen saal mein revenue double karke FY29 tak ₹1,000 crore tak pahunchayein.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.